- WELL provided updated comprehensive ROIC(1) metrics
for all clinics acquired in years 2022, 2023, and 2024 based on
exit run-rates in 2024. The results show ROIC figures of 41%, 24%,
and 28% respectively.
- WELL provides comprehensive performance metrics for all
Canadian clinics acquired in years 2022, 2023, and 2024 based on
exit run-rates in 2024. The results show effective multiples of
2.0x, 2.3x and 2.6x Adj. EBITDA respectively.
- WELL's overall M&A prospect pipeline now stands at 165
clinics generating over $440 million
of annual revenue at approximately double-digit Adj. EBITDA
margins. WELL's pipeline of signed LOIs currently stands at 19
clinics reflecting approximately $50
million in revenue at approximately double-digit Adj. EBITDA
margins.
- WELL also disclosed that it has no exposure to U.S. tariffs
against Canadian goods and any potential future tariffs imposed on
services would not harm the Company given that it currently does
not offer its healthcare software platform capabilities or care
delivery capabilities on a cross-border basis In addition, WELL has
significant exposure to the U.S. dollar as over 60% of its
revenues, Adj. EBITDA and cashflow is generated in U.S. dollars by
WELL's US based entities.
VANCOUVER, BC, Feb. 3, 2025
/PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX:
WHTCF) (the "Company" or "WELL"), a digital healthcare company
focused on positively impacting health outcomes by leveraging
technology to empower healthcare practitioners and their patients
globally, is pleased to announce key updates regarding the
financial performance of its acquired clinics, an update on its
current clinic prospect pipeline, and its positioning in light of
potential U.S.-Canada trade
tariffs.
WELL's Recent Clinic Cohorts Demonstrating Strong
Profitability and Growth
WELL continues to enhance its acquired clinics by implementing
its proprietary technology-driven transformation strategy. By tech
enabling clinicians, improving digital workflows and centralizing
administrative services, WELL has increased efficiency and
profitability across its expanding network. This has resulted in
time and resources being returned to care providers who are able to
increasingly focus on providing care and improving patient
outcomes.
Hamed Shahbazi, Founder and CEO
of WELL, commented "We are very pleased to share these metrics. The
results clearly show that our clinic ROIC(1) metrics
have significantly benefited by our clinic transformation program
and consistently delivered strong financial performance. We are now
taking steps to significantly increase our pace of growth in 2025
to meet our previously stated future long-term goal of reaching
$4 billion in revenues from Canadian
sources. We continue to execute on our goals by leveraging our
technology and expertise to compress acquisition multiples and
improve free cashflow generation reinforcing WELL's position as a
top-tier healthcare services provider and improving the
sustainability of the Canadian healthcare ecosystem."
The following table summarizes key performance data from the
Company's Canadian clinic M&A program:
|
Clinic
Cohort
|
2022
|
2023
|
2024
|
No. of Clinics
Purchased
|
7
|
29
|
95 (includes 59
licensees)
|
Aggregate Adj. EBITDA
Margin
Improvement (bps) since purchase
|
+585
|
+658
|
+133
|
Average Acquisition
Multiple of
Adj. EBITDA at Purchase
|
5.2x
|
nmf(2)
|
3.5x
|
Average Effective
Multiple of
Adj. EBITDA at Current Run-Rate
|
2.0x
|
2.3x
|
2.6x
|
ROIC(1)
|
41 %
|
24 %
|
28 %
|
|
3-year Average
ROIC(1) =
30%
|
|
Expanding M&A Pipeline and Growth Outlook
WELL's acquisition strategy continues to drive significant
growth, with a record-sized pipeline of opportunities in the
Canadian healthcare sector. The Company's M&A prospect pipeline
now includes 165 clinics generating over $440 million in annualized revenue at
approximately double-digit Adj. EBITDA margins. The Company's
near-term pipeline includes 19 signed LOIs representing
approximately $50M in revenue at
approximately double-digit Adj. EBITDA margins.
WELL's clinic acquisition strategy has accelerated
significantly, making 2024 its most active year for clinic
acquisitions in company history. The size of each new acquisition
cohort has grown, and WELL expects this momentum to expand even
further. Moving forward, the 2024 cohort alone is anticipated to
contribute approximately the same amount of Adj. EBITDA as the
combined 2022 and 2023 cohorts, making it the most Adj.
EBITDA-additive acquisition year in our Canadian Clinic program
since 2021.
This level of expansion reflects WELL's ability to efficiently
identify, acquire, and integrate high-quality clinics at attractive
valuations. Importantly, incremental ROICs on new acquisitions are
materially higher than the company-wide average, reinforcing the
growing value of tuck-in acquisitions. With WELL's acquisition
platform now maturing, the opportunity to integrate and optimize
additional clinics is greater than ever. This ROIC inflection is
being observed across our entire Canadian Clinics business care
clinics, demonstrating the scalability of WELL's operational
improvements and capital allocation discipline.
WELL's Business Model Resilient to U.S.-Canada
Tariffs
WELL can confirm that there are no material tariff threats to
its business today as it does not engage in cross-border sales
between Canada and the United States. While tariffs may
contribute to a challenging macroeconomic environment, WELL
operates in the healthcare sector, which is inherently defensive,
recession proof and insulated from much of the volatility affecting
other industries.
Even if the tariff matter were to escalate and include services,
WELL would still not be materially exposed as the Company does not
offer its healthcare software platform capabilities or care
delivery services on a cross-border basis between the two
countries. Additionally, WELL does not expect any material supply
chain impacts to any of its operations, as per the impacted list
shared by the Department of Finance Canada. Furthermore, WELL has
significant exposure to the US dollar as over 60% of its
revenues, Adj. EBITDA and cashflow is generated in US Dollars
by WELL's US based entities which also positions the Company
favourably in the event of currency volatility.
Eva Fong, Chief Financial Officer
of WELL, commented "Our business is built on a strong, resilient
foundation, and we are well-positioned to withstand any
macroeconomic challenges that may arise. Even if the potential
tariffs between the U.S. and Canada escalates to include services in
addition to goods, this would not affect our operations, as our
technology and care delivery services are not sold across the
border. We also believe that the current environment may create a
surge of 'buy Canadian' optimism which we believe could
significantly boost opportunities for our WELLSTAR technology
platform as it does compete from time to time with US companies for
material Canadian public sector contracts."
Footnotes:
- WELL defines Pre-Tax Unlevered ROIC for its Canadian clinic
cohorts, as the Adjusted EBITDA of the underlying businesses,
inclusive of clinic transformation costs, divided by the total
M&A consideration, including upfront cash, share consideration,
and realized and future earn-out payments. The Total M&A
consideration used in the Pre-Tax Unlevered ROIC calculation
excludes any allocation of corporate overhead, Property, Plant
& Equipment, and Working Capital. The non-GAAP financial
measures included in this non-GAAP ratio includes Adjusted EBITDA.
This non-GAAP ratio is not a standardized financial measure used to
prepare the Company's financial statements and may not be a
comparable to similar financial measures disclosed by other
issuers. The Company uses these non-GAAP standardized measures as
supplemental indicators of its financial and operating performance
which the Company believes allows for meaningful analysis of trends
in its clinic business.
- The Average Acquisition Multiple of EBITDA at Purchase for the
2023 clinic cohort is not meaningful, as the aggregate Adj. EBITDA
for the 2023 clinic cohort was negative, resulting in a negative
valuation multiple.
WELL HEALTH TECHNOLOGIES CORP.
Per: "Hamed Shahbazi"
Hamed Shahbazi
Chief Executive Officer, Chairman and Director
About WELL Health Technologies Corp.
WELL's mission is to tech-enable healthcare providers. We do
this by developing the best technologies, services, and support
available, which ensures healthcare providers are empowered to
positively impact patient outcomes. WELL's comprehensive healthcare
and digital platform includes extensive front and back-office
management software applications that help physicians run and
secure their practices. WELL's solutions enable more than 38,000
healthcare providers between the US and Canada and power the largest owned and
operated healthcare ecosystem in Canada with more than 200 clinics supporting
primary care, specialized care, and diagnostic services. In
the United States WELL's solutions
are focused on specialized markets such as the gastrointestinal
market, women's health, primary care, and mental health. WELL is
publicly traded on the Toronto Stock Exchange under the symbol
"WELL" and on the OTC Exchange under the symbol "WHTCF". To learn
more about the Company, please visit: www.well.company
View original content to download
multimedia:https://www.prnewswire.com/news-releases/well-provides-corporate-update-on-financial-performance-of-acquired-canadian-clinics-and-confirms-favourable-positioning-amidst-escalation-of-tariffs-between-the-us-and-canada-302366282.html
SOURCE WELL Health Technologies Corp.